March 17, 2015 | SOURCE: REGEN BIOPHARMA, INC.
Regen Receives Green Light From FDA to Proceed With GLP Safety Study in Support of Its HemaXellerate Investigational New Drug Application
March 3, 2015 | SOURCE: REGEN BIOPHARMA, INC.
Regen BioPharma Inc. Files Patent Application for Treatment of Myelodysplastic Syndrome Utilizing Gene Silencing Therapy
February 24, 2015 | SOURCE: REGEN BIOPHARMA, INC.
Regen BioPharma, Inc. Comments on dCellVax Cancer IDO-Targeting Technology in Relation to Bristol Myers Squibb-Flexus Biosciences, Inc. Announcement
February 24, 2015 | SOURCE: REGEN BIOPHARMA, INC.
Regen BioPharma Inc. Announces Preferred Stock Dividend
February 17, 2015 | SOURCE: REGEN BIOPHARMA, INC.
Regen BioPharma, Inc. Expands Management Team With the Addition of New CFO Todd Caven
January 14, 2015 | SOURCE: REGEN BIOPHARMA, INC.
Regen BioPharma, Inc. Provides Update on Company’s Progress and Areas of Specialization for 2015
January 8, 2015 | SOURCE: REGEN BIOPHARMA, INC.
Regen BioPharma Inc. Identifies Second Generation Gene Silencing Candidates for Blocking Cancer Stem Cell Gene Target
December 11, 2014 | SOURCE: Regen BioPharma, Inc.
Regen BioPharma Presented Novel Therapeutic Target for Leukemia and Myelodysplastic Syndrome at the American Society of Hematology Annual Meeting
December 1, 2014 | SOURCE: Regen BioPharma, Inc.
Regen BioPharma Scheduled to Make Presentation at American Society for Hematology’s 56th Annual Meeting in San Francisco December 6th – 9th
November 25, 2014 | SOURCE: Regen BioPharma, Inc.
Regen BioPharma Acquires University of Toronto Cancer Stem Cell Intellectual Property